Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sagard
Toronto, Ontario, Canadasagard.com ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
Since inception of its healthcare strategy in December 2019, Sagard has invested over $1 billion acquiring royalties on innovative drugs such as Jemperli (dostarlimab), Voquezna (vonoprazan), Tibsovo (ivosidenib), Hemgenix (etranacogene dezaparvovec-drlb), Tyvaso DPI (treprostinil inhalation powder) and ZYNYZ (retifanlimab-dlwr). These are all approved or near-commercialization therapies.
- Therapeutic areas
- OncologyPulmonologyHematologyGastroenterologyCardiovascularInfectious Diseases
- Modalities
- Small moleculeMonoclonal antibodyGene therapyMedical devices
- Industry
- Investors
02
Partnerships
Nuvation BioMacroGenicsPhathom PharmaceuticalsMannKind Corporation/United TherapeuticsMarinus Pharmaceuticals
Beyond the preview
Go deeper on Sagard.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sagard.